

# IHC Offerings

As part of our genomic sequencing portfolio, Tempus offers four (4) different PD-L1 IHC clones to assess PD-L1 expression, a DNA mismatch repair (MMR) IHC panel, as well as a selection of reference laboratory IHC stains.

## How to order a specific clone

Staining results from the available IHCs below will be reported according to their own interpretation and expression thresholds.

Certain cancer types may have multiple relevant clones that correspond with therapeutic options. The tables below may help to aid the selection of a specific clone that is most relevant to your patient; however any clone(s) may be ordered at the physician's discretion.

The 22C3 clone is the default option, unless a different clone is selected for PD-L1 testing.

Tempus IHC offerings include a range of PD-L1 clones, each tailored to specific cancer types:

CANCER TYPE	CLONE	SCORING METHOD
All cancer types	MMR Panel	MSH6, MSH2, MLH1, PMS2
Cervical Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
Esophageal Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
Gastric/GEJ Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
Head and Neck Squamous Cell Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
Non-Small Cell Lung Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
	28-8	Tumor Cell Staining (TC)%
	SP142	Tumor Cell Staining (TC)%; Tumor-Infiltrating Immune Cell Staining (IC)%
	SP263	Tumor Cell Staining (TC)%
Triple Negative Breast Cancer	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)
Other cancer types	22C3	Tumor Proportion Score (TPS)%; Combined Positive Score (CPS)

## IHC offerings (powered by NeoGenomics):

CANCER TYPE	IHC	SCORING METHOD
Epithelial Ovarian Cancer	FOLR1 (FR $\alpha$ )	Expression percentage (2+/3+ staining)
Breast Cancer	HER2 with reflex to ERBB2 FISH testing**	0-3+ scale (Reflex with 2+ result)
Gastric Cancer	HER2 with reflex to ERBB2 FISH testing**	0-3+ scale (Reflex with 2+ result)
	CLDN18	Expression percentage (2+/3+ staining)
Other cancer types	HER2	0-3+ scale (No reflex)

## IHC Add-on options for testing

IHC	PD-L1	MMR	FOLR1 (powered by NeoGenomics)	HER2 (powered by NeoGenomics)	CLDN18 (powered by NeoGenomics)
Tempus xT	✓	✓	✓	✓	✓
Tempus xR	✓	✓	✓	✓	✓
Tempus xE	✓	✓			

\* In accordance with appropriate ASCO/CAP and NCCN guidelines, your order will be reflexed based on the IHC scores listed for the breast or gastric cancer type1-4

† HER2 testing is recommended for patients with metastatic colorectal cancer (CRC). CRC specimens are not scored in accordance with CRC guidelines5,6, but instead fall under the HER2 gastric scoring criteria and remain candidates for FISH reflex

1 NCCN Clinical Practice Guidelines in Oncology. Breast. Version 4.2024.

2 Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. *J Clin Oncol.* 2023;41(22):3867-3872.

3 NCCN Clinical Practice Guidelines in Oncology. Gastric. Version 4.2024.

4 Bartley AN, Washington MK, Ventura CB, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *Arch Pathol Lab Med.* 2016;140(12):1345-1363.

5 NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 5.2024.

6 NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 4.2024.